Emcutix Biopharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 2 Months 18 Days
About Emcutix Biopharmaceuticals
The Company is engaged in the Paper Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Emcutix Biopharmaceuticals Limited India is Govindan Narayanan as CEO. Sanjay Mehta, Sunil Mehta, Satish Mehta, and Two other members serve as directors at the Company.
- CIN/LLPIN
U21002PN2024PLC234721
- Company No.
234721
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
03 Oct 2024
- Date of AGM
-
- Date of Balance Sheet
-
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Emcutix Biopharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Govindan Narayanan | CEO | 28-Nov-2024 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Govindan Narayanan  | Whole-Time Director | 15-Oct-2024 | Current |
| Sanjay Mehta | Director | 03-Oct-2024 | Current |
| Sunil Mehta | Director | 03-Oct-2024 | Current |
| Satish Mehta | Additional Director | 04-Oct-2024 | Current |
Vikas Thapar  | Director | 03-Oct-2024 | Current |
Financial Performance and Corporate Structure Insights of Emcutix Biopharmaceuticals.
Enhance accessibility to Emcutix Biopharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Emcutix Biopharmaceuticals?
Unlock access to Emcutix Biopharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Emcure Pharmaceuticals LimitedActive 43 years 8 monthsSunil Mehta and Satish Mehta are mutual person
Gennova Biopharmaceuticals LimitedActive 23 years 6 monthsSunil Mehta and Satish Mehta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Emcutix Biopharmaceuticals?
Unlock and access historical data on people associated with Emcutix Biopharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emcutix Biopharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emcutix Biopharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
